
Sign up to save your podcasts
Or


Listen in as our expert panel discusses which diabetes meds have cardiovascular (CV) benefits. We’ll review the evidence and discuss the pros and cons of SGLT2 inhibitors (dapagliflozin, empagliflozin, etc) and GLP-1 agonists (dulaglutide, semaglutide, etc) in patients with or at risk for CV disease.
Special Guests:
TRC Editorial Advisory Board Participant:
For the purposes of disclosure, Dr. Schumacher reports a relevant financial relationship [CGM for diabetes management] with Abbott (speakers bureau).
The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.
This podcast is an excerpt from one of TRC’s monthly live CE webinars, the full webinar originally aired in February 2025.
TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist’s Letter, Pharmacy Technician’s Letter,or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.
Claim Credit
The clinical resources mentioned during the podcast are part of a subscription to Pharmacist’s Letter, Pharmacy Technician’s Letter, and Prescriber Insights:
Send us a text
Email us: [email protected].
The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment.
Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.
Learn more about our product offerings at trchealthcare.com.
By TRC Healthcare4.8
3636 ratings
Listen in as our expert panel discusses which diabetes meds have cardiovascular (CV) benefits. We’ll review the evidence and discuss the pros and cons of SGLT2 inhibitors (dapagliflozin, empagliflozin, etc) and GLP-1 agonists (dulaglutide, semaglutide, etc) in patients with or at risk for CV disease.
Special Guests:
TRC Editorial Advisory Board Participant:
For the purposes of disclosure, Dr. Schumacher reports a relevant financial relationship [CGM for diabetes management] with Abbott (speakers bureau).
The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.
This podcast is an excerpt from one of TRC’s monthly live CE webinars, the full webinar originally aired in February 2025.
TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist’s Letter, Pharmacy Technician’s Letter,or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.
Claim Credit
The clinical resources mentioned during the podcast are part of a subscription to Pharmacist’s Letter, Pharmacy Technician’s Letter, and Prescriber Insights:
Send us a text
Email us: [email protected].
The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment.
Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.
Learn more about our product offerings at trchealthcare.com.

699 Listeners

500 Listeners

102 Listeners

291 Listeners

258 Listeners

3,349 Listeners

1,156 Listeners

733 Listeners

196 Listeners

510 Listeners

426 Listeners

373 Listeners

152 Listeners

4 Listeners

7 Listeners